FASN and neoplasm: Lipid-targeting (e.g., FASN, Acetyl-CoA carboxylase (ACC), Stearoyl-CoA desaturase 1 (SCD1) inhibitors) acts as a metabolic trap: impairing tumour-lipid supply, altering membrane composition and increasing vulnerability to immune attack.